{"transactions":[{"id":898512,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-18T17:05:18.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":7269,"price":1.89,"value":13738.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025."}],"balance_after":298801,"source":{"system":"sec-edgar","filing":"0001470831-26-000180","document":"wk-form4_1771452315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000147083126000180/wk-form4_1771452315.xml","form_type":"4"}},{"id":898511,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-18T17:05:18.000Z","date":"2026-02-14","kind":"exercise","planned":false,"acquired":true,"shares":20950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025."}],"balance_after":306070,"source":{"system":"sec-edgar","filing":"0001470831-26-000180","document":"wk-form4_1771452315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000147083126000180/wk-form4_1771452315.xml","form_type":"4"}},{"id":898510,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-18T17:05:18.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1735,"price":1.89,"value":3279.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person."}],"balance_after":306070,"source":{"system":"sec-edgar","filing":"0001470831-26-000180","document":"wk-form4_1771452315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000147083126000180/wk-form4_1771452315.xml","form_type":"4"}},{"id":898509,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-18T17:05:18.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025."}],"balance_after":307805,"source":{"system":"sec-edgar","filing":"0001470831-26-000180","document":"wk-form4_1771452315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000147083126000180/wk-form4_1771452315.xml","form_type":"4"}},{"id":898508,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-18T17:05:18.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones."}],"balance_after":307805,"source":{"system":"sec-edgar","filing":"0001470831-26-000180","document":"wk-form4_1771452315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000147083126000180/wk-form4_1771452315.xml","form_type":"4"}},{"id":1265048,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T16:55:16.000Z","date":"2025-02-14","kind":"grant","planned":true,"acquired":true,"shares":84700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025."}],"balance_after":84700,"derivative":{"exercise_price":3.18,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":84700},"source":{"system":"sec-edgar","filing":"0001662579-25-000019","document":"wk-form4_1739915710.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257925000019/wk-form4_1739915710.xml","form_type":"4"}},{"id":1265047,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-18T16:55:16.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":669,"price":3.15,"value":2107.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2024."}],"balance_after":107805,"source":{"system":"sec-edgar","filing":"0001662579-25-000019","document":"wk-form4_1739915710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257925000019/wk-form4_1739915710.xml","form_type":"4"}},{"id":1265046,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-18T16:55:16.000Z","date":"2025-02-14","kind":"tax_withholding","planned":true,"acquired":false,"shares":2368,"price":3.18,"value":7530.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") and does not represent a sale by the Reporting Person."}],"balance_after":108474,"source":{"system":"sec-edgar","filing":"0001662579-25-000019","document":"wk-form4_1739915710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257925000019/wk-form4_1739915710.xml","form_type":"4"}},{"id":1265045,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-18T16:55:16.000Z","date":"2025-02-14","kind":"sale","planned":true,"acquired":false,"shares":490,"price":3.15,"value":1543.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2024."}],"balance_after":110842,"source":{"system":"sec-edgar","filing":"0001662579-25-000019","document":"wk-form4_1739915710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257925000019/wk-form4_1739915710.xml","form_type":"4"}},{"id":1265044,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-18T16:55:16.000Z","date":"2025-02-14","kind":"grant","planned":true,"acquired":true,"shares":56500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026."}],"balance_after":111332,"source":{"system":"sec-edgar","filing":"0001662579-25-000019","document":"wk-form4_1739915710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257925000019/wk-form4_1739915710.xml","form_type":"4"}},{"id":1265043,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-18T16:55:16.000Z","date":"2025-02-13","kind":"tax_withholding","planned":true,"acquired":false,"shares":1735,"price":3.2,"value":5552.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") and does not represent a sale by the Reporting Person."}],"balance_after":54832,"source":{"system":"sec-edgar","filing":"0001662579-25-000019","document":"wk-form4_1739915710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257925000019/wk-form4_1739915710.xml","form_type":"4"}},{"id":1369883,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2024-11-12T16:17:43.000Z","date":"2024-11-07","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":10500,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001662579-24-000104","document":"wk-form4_1731446256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257924000104/wk-form4_1731446256.xml","form_type":"4"}},{"id":1369882,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-11-12T16:17:43.000Z","date":"2024-11-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":1102,"price":6.04,"value":6656.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":56567,"source":{"system":"sec-edgar","filing":"0001662579-24-000104","document":"wk-form4_1731446256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257924000104/wk-form4_1731446256.xml","form_type":"4"}},{"id":1369881,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-11-12T16:17:43.000Z","date":"2024-11-07","kind":"exercise","planned":false,"acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":57669,"source":{"system":"sec-edgar","filing":"0001662579-24-000104","document":"wk-form4_1731446256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257924000104/wk-form4_1731446256.xml","form_type":"4"}},{"id":1405918,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2024-09-17T17:12:36.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":14250,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001662579-24-000083","document":"wk-form4_1726607550.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257924000083/wk-form4_1726607550.xml","form_type":"4"}},{"id":1405917,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-09-17T17:12:36.000Z","date":"2024-09-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":661,"price":6.36,"value":4203.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":53919,"source":{"system":"sec-edgar","filing":"0001662579-24-000083","document":"wk-form4_1726607550.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257924000083/wk-form4_1726607550.xml","form_type":"4"}},{"id":1405916,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-09-17T17:12:36.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":54580,"source":{"system":"sec-edgar","filing":"0001662579-24-000083","document":"wk-form4_1726607550.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257924000083/wk-form4_1726607550.xml","form_type":"4"}},{"id":1587888,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T19:28:56.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this option shall vest and become exercisable on January 3, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":115000,"derivative":{"exercise_price":19,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001662579-24-000032","document":"wk-form4_1709944127.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257924000032/wk-form4_1709944127.xml","form_type":"4"}},{"id":1587887,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T19:28:56.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this option shall vest and become exercisable on January 3, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":33.23,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001662579-24-000032","document":"wk-form4_1709944127.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257924000032/wk-form4_1709944127.xml","form_type":"4"}},{"id":1641741,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T17:03:05.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":122800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024."}],"balance_after":122800,"derivative":{"exercise_price":7.31,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":122800},"source":{"system":"sec-edgar","filing":"0001662579-24-000015","document":"wk-form4_1708034573.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257924000015/wk-form4_1708034573.xml","form_type":"4"}},{"id":1641740,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-15T17:03:05.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":27300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025."}],"balance_after":52330,"source":{"system":"sec-edgar","filing":"0001662579-24-000015","document":"wk-form4_1708034573.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257924000015/wk-form4_1708034573.xml","form_type":"4"}},{"id":1641739,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-15T17:03:05.000Z","date":"2024-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1735,"price":6.53,"value":11329.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") and does not represent a sale by the Reporting Person."}],"balance_after":25030,"source":{"system":"sec-edgar","filing":"0001662579-24-000015","document":"wk-form4_1708034573.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257924000015/wk-form4_1708034573.xml","form_type":"4"}},{"id":1778069,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-19T19:23:01.000Z","date":"2023-09-18","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date."}],"balance_after":120000,"derivative":{"exercise_price":2.15,"expiration_date":"2033-09-17","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001662579-23-000099","document":"wk-form4_1695165770.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257923000099/wk-form4_1695165770.xml","form_type":"4"}},{"id":1792275,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-08-31T16:09:55.000Z","date":"2023-08-30","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":16500,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001662579-23-000081","document":"wk-form4_1693512585.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257923000081/wk-form4_1693512585.xml","form_type":"4"}},{"id":1792274,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-08-31T16:09:55.000Z","date":"2023-08-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":661,"price":2.93,"value":1936.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":26765,"source":{"system":"sec-edgar","filing":"0001662579-23-000081","document":"wk-form4_1693512585.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257923000081/wk-form4_1693512585.xml","form_type":"4"}},{"id":1792273,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-08-31T16:09:55.000Z","date":"2023-08-30","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":27426,"source":{"system":"sec-edgar","filing":"0001662579-23-000081","document":"wk-form4_1693512585.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257923000081/wk-form4_1693512585.xml","form_type":"4"}},{"id":2014213,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-15T16:45:26.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023."}],"balance_after":90000,"derivative":{"exercise_price":5.67,"expiration_date":"2033-02-12","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001662579-23-000037","document":"wf-form4_167649750908844.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257923000037/wf-form4_167649750908844.xml","form_type":"4"}},{"id":2014212,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-02-15T16:45:26.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024."}],"balance_after":25176,"source":{"system":"sec-edgar","filing":"0001662579-23-000037","document":"wf-form4_167649750908844.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257923000037/wf-form4_167649750908844.xml","form_type":"4"}},{"id":2039098,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-02-01T16:10:28.000Z","date":"2023-01-30","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":18750,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001662579-23-000022","document":"wf-form4_167528579820409.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257923000022/wf-form4_167528579820409.xml","form_type":"4"}},{"id":2039097,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-02-01T16:10:28.000Z","date":"2023-01-30","kind":"tax_withholding","acquired":false,"shares":1222,"price":7.78,"value":9507.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":5176,"source":{"system":"sec-edgar","filing":"0001662579-23-000022","document":"wf-form4_167528579820409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257923000022/wf-form4_167528579820409.xml","form_type":"4"}},{"id":2039096,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-02-01T16:10:28.000Z","date":"2023-01-30","kind":"exercise","acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":6398,"source":{"system":"sec-edgar","filing":"0001662579-23-000022","document":"wf-form4_167528579820409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000166257923000022/wf-form4_167528579820409.xml","form_type":"4"}},{"id":2233258,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-06-14T16:45:11.000Z","date":"2022-05-26","kind":"tax_withholding","acquired":false,"shares":1102,"price":7.01,"value":7725.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":2648,"source":{"system":"sec-edgar","filing":"0001209191-22-036711","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000120919122036711/doc4a.xml","form_type":"4/A","original_submission_date":"2022-05-27"}},{"id":2254296,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2022-05-27T16:15:28.000Z","date":"2022-05-25","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":22500,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001209191-22-032510","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000120919122032510/doc4.xml","form_type":"4"}},{"id":2254295,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":66004,"kind":"person","name":"Boyle Scott N","position":1,"cik":"0001913897","reported_name":"Boyle Scott N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-05-27T16:15:28.000Z","date":"2022-05-25","kind":"exercise","acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":3750,"source":{"system":"sec-edgar","filing":"0001209191-22-032510","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1913897/000120919122032510/doc4.xml","form_type":"4"}}]}